Lydall, Inc. (LDL) - NYSE
  • Today, 4:38 PM
    • Lydall (NYSE:LDL): Q1 EPS of $0.54 beats by $0.03.
    • Revenue of $129.7M (+1.9% Y/Y) misses by $1.24M.
    • Press Release
    | Today, 4:38 PM
  • Wed, Feb. 24, 4:41 PM
    • Lydall (NYSE:LDL): Q4 EPS of $0.46 misses by $0.01.
    • Revenue of $131.39M (+3.0% Y/Y) beats by $5.02M.
    • Press Release
    | Wed, Feb. 24, 4:41 PM
  • Nov. 3, 2015, 5:02 PM
    • Lydall (NYSE:LDL): Q3 EPS of $0.59 beats by $0.10.
    • Revenue of $131.2M (-2.3% Y/Y) beats by $1.3M.
    | Nov. 3, 2015, 5:02 PM
  • Oct. 31, 2015, 12:51 PM
    | Oct. 31, 2015, 12:51 PM | 290 Comments
  • Oct. 1, 2015, 3:39 PM
    • U.S. auto sales sizzled in September as the combination of low gas prices and subdued auto loan rates motivated consumers to make a move. The monthly tally was influence a bit by an extra selling day and a comparison to last year when part of the Labor Day weekend was in August.
    • The Detroit Three led the way with strong sales volume and solid pricing in a development that takes some of the sting off the Volkswagen scandal which rocked the sector.
    • The industry-wide run rate for the month is estimated to be 18.7M annual sale to match the highest level of activity since 2005.
    • Fiat Chrysler Automobiles (FCAU +1.9%) is the only major automaker putting in a strong gain on the day, although most automaker stocks are ahead of the DJIA.
    • A large number of auto parts stocks are also beating market averages on enthusiasm over the strong numbers. Lydall (NYSE:LDL), Delphi Automotive (NYSE:DLPH), Modine Manufacturing (NYSE:MOD), and Tenneco (NYSE:TEN) are leading the mini-charge.
    | Oct. 1, 2015, 3:39 PM | 7 Comments
  • Aug. 11, 2015, 10:15 AM
    • In a letter published in the Journal of the American Medical Association (AMA), CVS Health (CVS -0.5%) urges heart specialists to revamp guidelines for treating patients with high cholesterol to provide clarity on how best to choose the best and most cost effective therapy now that expensive new drugs called PCSK9 inhibitors are now on (or will soon be on) the market.
    • PCSK9 inhibitors, led by recently-approved Praluent (alirocumab) (SNY -0.4%)(REGN -0.8%) and soon-to-be-approved Repatha (evolocumab), are, at least initially, more than 20 times more expensive than statins. Pharmacy benefit managers, like CVS, aim to control costs by extracting significant discounts from manufacturers and controlling patient access to the pricier drugs.
    • CVS wants the guidelines to include specific LDL targets, which older guidelines did before new ones issued in 2013 did away with them. The emphasis now is on a patient's risk of developing heart disease as the main determinant for more intensive treatment. Unsurprisingly, the American College of Cardiology and the AMA have shown scant enthusiasm for revisiting the issue.
    • CVS Chief Medical Officer Dr. Troyen Brennan says that if the guidelines are not changed, then CVS will use its own targets, which will vary depending on each patent's medical history. "We expect patients to first use statins. If they can't use statins or can't make (NYSE:LDL) targets, then they would use PCSK9 inhibitors."
    • The PDUFA date for Amgen's (AMGN -1%) Repatha is August 27.
    | Aug. 11, 2015, 10:15 AM | 16 Comments
  • Aug. 5, 2015, 12:08 AM
    • Lydall (NYSE:LDL): Q2 EPS of $0.64 beats by $0.17.
    • Revenue of $134.6M (-9.5% Y/Y) misses by $6.5M.
    | Aug. 5, 2015, 12:08 AM
  • Jun. 29, 2015, 3:58 PM
    • Calgon Carbon (CCC -8.1%) is sharply lower after the Supreme Court ruled against the EPA's recent mercury emissions mandate, which sent coal stock prices soaring.
    • CCC says that while the Court's decision is disappointing, mercury control regulations are in place in many states and Canada that already have established a sizable market; CCC says it continues to expect to increase its activated carbon mercury removal market revenues by ~50% this year.
    • Specialty chemical companies Albemarle (ALB -4.9%) and Cabot (CBT -6.6%), which also may have benefited from increased sales of bromine and activated carbon used to reduce mercury, fell sharply.
    • Also posting big losses: ADES -9.6%, GTLS -5.4%, LDL -5.1%, ESE -2.7%, ECL -2.4%, DHR -1.2%.
    | Jun. 29, 2015, 3:58 PM | 1 Comment
  • May 29, 2015, 10:39 AM
    • Automobile industry supplier stocks are tilting lower after WABCO and Modine Manufacturing issued guidance below the expectations of analysts.
    • F/X pressure and some uncertainty in the markets in Brazil and China are weighing on the sector.
    • Decliners: WABCO (NYSE:WBC) -2.9%, Modine Manufacturing (NYSE:MOD) -2.5%, Meritor (NYSE:MTOR) -2.4%, Motorcar Parts of America (NASDAQ:MPAA) -2.3%, Westport Innovations (NASDAQ:WPRT) -2.0%, Federal-Mogul (NASDAQ:FDML) -1.8%, Stoneridge (NYSE:SRI) -1.3%, Lydall (NYSE:LDL) -1.3%, Cooper-Standard Holdings (NYSE:CPS) -1.2%.
    | May 29, 2015, 10:39 AM | 1 Comment
  • Apr. 30, 2015, 7:04 AM
    • Lydall (NYSE:LDL): Q1 EPS of $0.42 beats by $0.02.
    • Revenue of $127.3M (+1.7% Y/Y) misses by $1.1M.
    | Apr. 30, 2015, 7:04 AM
  • Mar. 3, 2015, 7:05 AM
    • Lydall (NYSE:LDL): Q4 EPS of $0.34 beats by $0.04.
    • Revenue of $127.6M (+27.7% Y/Y) beats by $1.1M.
    | Mar. 3, 2015, 7:05 AM
  • Mar. 2, 2015, 1:57 PM
    • There's a broad rally in auto parts stocks underway after a strong read on sales in some key European markets.
    • Sales in Spain rose 26% Y/Y in February, while sales improved 7% in Germany and 4.1% in France.
    • February U.S. sales are due to be reported tomorrow by manufacturers.
    • Gainers: Federal-Mogul (NASDAQ:FDML)+4.1%, Westport Innovations (NASDAQ:WPRT) +2.6%, Modine Manufacturing (NYSE:MOD) +2.6%, Dana Holding (NYSE:DAN) +2.5%, Visteon (NYSE:VC) +2.4%, BorgWarner (NYSE:BWA) +2.4%, Lear (NYSE:LEA) +2.4%, Lydall (NYSE:LDL) +2.2%, Johnson Controls (NYSE:JCI) +2.2%, Delphi Automotive (NYSE:DLPH) +2.0%.
    | Mar. 2, 2015, 1:57 PM
  • Nov. 5, 2014, 7:21 AM
    • Lydall (NYSE:LDL): Q3 EPS of $0.43 beats by $0.10.
    • Revenue of $134.2M (+36.9% Y/Y) misses by $0.8M.
    | Nov. 5, 2014, 7:21 AM
  • Jul. 31, 2014, 7:21 AM
    • Lydall (NYSE:LDL): Q2 EPS of $0.64
    • Revenue of $148.8M (+47.2% Y/Y)
    | Jul. 31, 2014, 7:21 AM
  • May 5, 2014, 7:18 AM
    • Lydall (LDL): Q1 EPS of $0.40.
    • Revenue of $125.2M (+26.5% Y/Y).
    | May 5, 2014, 7:18 AM
  • Mar. 5, 2014, 7:44 AM
    • LYDALL (LDL): Q4 EPS of $0.25.
    • Revenue of $99.9M (+10.4% Y/Y).
    | Mar. 5, 2014, 7:44 AM
Company Description
Lydall, Inc. engages in the design, manufacture, and supply of technologically advanced products. It produces specialty engineered filtration non-woven media, industrial thermal insulating solutions, and thermal and acoustical barriers for filtration and separation and heat abatement and sound... More
Industry: Synthetics
Country: United States